fbpx
  • Home
  • Search Results

Research Studies

UNC-Chapel Hill Division of Hematology

28 studies match your search
By physician referral or invitation only

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (CPX-351) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Can we lower the chances of your acute myeloid leukemia (AML) growing by adding a drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your AML. The usual approach is defined as care most people get for AML.

Age & Gender
  • 18 years ~ 75 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Testing CC-486 Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, ransformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements

To determine if patients that are 75 years of age or older who were recently diagnosed with DLBCL be able to take the study drug CC-486 (oral azacitidine) plus the standard drug therapy that fights cancer cells for at least 4 cycles of therapy (a cycle = 21 days; 4 cycles is 12 weeks) without significantly more side effects than patients taking the standard drug therapy alone; have longer, shorter, or the same amount of time without the disease getting worse (progression) than patients taking the standard drug therapy alone; live longer, live the same amount of time, or live a shorter amount of time than patients taking the standard drug therapy alone. This study is being done to find out if this approach is better or worse than the usual approach for the DLBCL. The usual approach is defined as care most people get for DLBCL.

Age & Gender
  • 75 years ~ 99 years
  • Male, Female
Study Interest
  • Aging
  • Cancer (Lymphoma)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Treatment Satisfaction with Avatrombopag in Chronic ITP patients

Current treatments of Chronic ITP include Eltrombopag, Romiplostim, and Avatrombopag (DOPTELET). However, Doptelet provides unique benefits in that it can be orally taken as a pill once daily without restrictions on diet or requiring a provider unlike the other available treatments. This study aims to characterize the switch from other available treatments to doptelet and measure the safety, efficacy, and patient reported satisfaction with avatrombopag for 90 days.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Genetics and Genetic Disorders
  • Rare Diseases
  • and 3 more
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. The dose administered is 50 x 10^6 cells (flat dosing).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Other Cancers)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Post Prostate Surgery Study of Standard vs Enhanced Androgen Deprivation Therapy

The purpose of this study is to determine whether, in men with post-prostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog-based ADT alone.

Age & Gender
  • 18 years ~ 99 years
  • Male
Study Interest
  • Cancer (Prostate)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Mismatched Unrelated Donor

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

Age & Gender
  • 1 years ~ 66 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia)
  • Transplant
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

SCD Biochip

To develop an SCD Biochip with which to examine key cellular properties and interactions, including RBC and WBC cellular and adhesive properties, and circulating endothelial hematopoietic precursor cell characteristics. To correlate SCD Biochip function in heterogeneous SCD populations, including HbSS and HbSC at a range of ages, and in those with acute and chronic complications and compared with normal controls.

Age & Gender
  • 12 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Minority Health
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Geriatric conditions and how they shape the experiences of older adults with myeloma

To understand how myeloma and its associated treatments affect the physical, cognitive (mental) health and overall well-being of an older adult, throughout the treatment/myeloma course.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Pomalidomide for HHT patients

To see if pomalidomide is an effective treatment for epistaxis in patients with HHT.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
Visit Location
100% Remote (online, phone, text)
By physician referral or invitation only

Understanding Causes of Outcome Disparities in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL)

The purpose of this study is to understand why there are differences in outcomes in adolescents and young adults treated for ALL.

Age & Gender
  • 15 years ~ 39 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pediatric Cancers, Leukemia)
  • Child and Teen Health
Visit Location
100% Remote (online, phone, text)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research